Compare Stocks: ARCT, MAZE, COAG, and ANAB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$46.59 -2.7%	$54.87	$20.18 ▼ $72.36	$1.40B	0.76	690,455 shs	221,001 shs
ARCT Arcturus Therapeutics	$12.77 -1.8%	$12.31	$5.50 ▼ $24.17	$363.67M	2.48	625,542 shs	219,529 shs
COAG Hemab Therapeutics	$28.45 +0.3%	$43.66	$23.00 ▼ $55.42	$1.33B	N/A	376,885 shs	189,243 shs
MAZE Maze Therapeutics	$26.20 -0.9%	$26.90	$21.95 ▼ $53.65	$1.46B	2.16	662,668 shs	165,123 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	-2.66%	-4.92%	-15.69%	-26.72%	+58.31%
ARCT Arcturus Therapeutics	-11.32%	-5.11%	-17.83%	+78.08%	-38.12%
COAG Hemab Therapeutics	-7.26%	-12.98%	-36.12%	-16.29%	+2,836,999,900.00%
MAZE Maze Therapeutics	0.00%	-2.18%	+0.84%	-17.38%	-3.96%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$46.59 -2.7%	$54.87	$20.18 ▼ $72.36	$1.40B	0.76	690,455 shs	221,001 shs
ARCT Arcturus Therapeutics	$12.77 -1.8%	$12.31	$5.50 ▼ $24.17	$363.67M	2.48	625,542 shs	219,529 shs
COAG Hemab Therapeutics	$28.45 +0.3%	$43.66	$23.00 ▼ $55.42	$1.33B	N/A	376,885 shs	189,243 shs
MAZE Maze Therapeutics	$26.20 -0.9%	$26.90	$21.95 ▼ $53.65	$1.46B	2.16	662,668 shs	165,123 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	-2.66%	-4.92%	-15.69%	-26.72%	+58.31%
ARCT Arcturus Therapeutics	-11.32%	-5.11%	-17.83%	+78.08%	-38.12%
COAG Hemab Therapeutics	-7.26%	-12.98%	-36.12%	-16.29%	+2,836,999,900.00%
MAZE Maze Therapeutics	0.00%	-2.18%	+0.84%	-17.38%	-3.96%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.71	Moderate Buy	$77.79	66.79% Upside
ARCT Arcturus Therapeutics	2.64	Moderate Buy	$22.43	75.50% Upside
COAG Hemab Therapeutics	2.57	Moderate Buy	$51.40	79.85% Upside
MAZE Maze Therapeutics	3.08	Buy	$63.40	141.02% Upside

Current Analyst Ratings Breakdown

Latest ARCT, MAZE, COAG, and ANAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/30/2026	ANAB AnaptysBio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$70.00 ➝ $60.00
9/25/2026	COAG Hemab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
9/24/2026	ARCT Arcturus Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/24/2026	ARCT Arcturus Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$23.00 ➝ $20.00
9/24/2026	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$8.00 ➝ $20.00
9/24/2026	MAZE Maze Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$110.00
9/23/2026	MAZE Maze Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$50.00
9/23/2026	ANAB AnaptysBio	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$90.00 ➝ $81.00
9/23/2026	MAZE Maze Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$50.00
9/23/2026	MAZE Maze Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$48.00
9/22/2026	ANAB AnaptysBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$95.00

(Data available from 10/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$234.60M	5.94	N/A	N/A	$1.34 per share	34.80
ARCT Arcturus Therapeutics	$18.72M	19.40	N/A	N/A	$7.53 per share	1.70
COAG Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
MAZE Maze Therapeutics	$167.50M	8.72	N/A	N/A	$7.38 per share	3.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$13.23M	$5.37	8.70	19.27	N/A	82.37%	112.00%	2.20%	11/3/2026 (Estimated)
ARCT Arcturus Therapeutics	-$65.78M	-$3.31	N/A	N/A	N/A	-317.62%	-46.54%	-36.46%	11/9/2026 (Estimated)
COAG Hemab Therapeutics	N/A	-$24.78	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MAZE Maze Therapeutics	-$131.12M	-$2.52	N/A	N/A	N/A	N/A	-34.94%	-30.18%	N/A

Latest ARCT, MAZE, COAG, and ANAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	ANAB AnaptysBio	-$1.84	N/A	N/A	N/A	$25.56 million	N/A
9/21/2026	Q2 2026	ANAB AnaptysBio	-$0.4650	$5.11	+$5.5750	$5.11	$14.06 million	$27.49 million
8/11/2026	Q2 2026	COAG Hemab Therapeutics	-$0.63	-$0.80	-$0.17	-$0.80	N/A	N/A
8/11/2026	Q2 2026	MAZE Maze Therapeutics	-$0.76	-$0.76	N/A	-$0.76	N/A	N/A
8/7/2026	Q2 2026	ARCT Arcturus Therapeutics	-$0.9964	-$0.84	+$0.1564	-$0.84	$3.11 million	$2.96 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	$0.71	5.59%	N/A	N/A	N/A
COAG Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
MAZE Maze Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	7.58	7.58
ARCT Arcturus Therapeutics	N/A	5.88	5.88
COAG Hemab Therapeutics	N/A	35.85	35.85
MAZE Maze Therapeutics	0.09	18.31	18.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
ARCT Arcturus Therapeutics	94.54%
COAG Hemab Therapeutics	N/A
MAZE Maze Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	31.50%
ARCT Arcturus Therapeutics	17.80%
COAG Hemab Therapeutics	N/A
MAZE Maze Therapeutics	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	104	29.90 million	20.48 million	Optionable
ARCT Arcturus Therapeutics	111	28.42 million	23.36 million	Optionable
COAG Hemab Therapeutics	59	46.71 million	N/A	N/A
MAZE Maze Therapeutics	141	55.55 million	52.61 million	N/A

ARCT, MAZE, COAG, and ANAB Headlines

Recent News About These Companies

MAZE Stock Gets Increased EPS Forecast from HC Wainwright

October 7 at 7:12 AM | americanbankingnews.com

HC Wainwright Issues Optimistic Estimate for MAZE Earnings

October 7 at 7:11 AM | marketbeat.com

Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026

October 6 at 4:05 PM | globenewswire.com

Maze Therapeutics, Inc. (MAZE) Interactive Stock Chart - Yahoo Finance

October 6 at 2:04 PM | finance.yahoo.com

Research Analysts Set Expectations for MAZE Q2 Earnings

October 6 at 6:29 AM | americanbankingnews.com

What is HC Wainwright's Estimate for MAZE Q2 Earnings?

October 6 at 6:26 AM | marketbeat.com

3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight (MAZE)

...

October 5 at 10:55 AM | marketbeat.com

Allogene Therapeutics (NASDAQ:ALLO) and Maze Therapeutics (NASDAQ:MAZE) Financial Analysis

October 4 at 12:14 AM | americanbankingnews.com

Maze Therapeutics' CMO Harold Bernstein Executes 16,141 Share Sale via 10b5-1 Plan

October 4 at 9:44 AM | kalkinemedia.comK

Critical Contrast: Fate Therapeutics (NASDAQ:FATE) & Maze Therapeutics (NASDAQ:MAZE)

October 4 at 5:00 AM | americanbankingnews.com

Maze Therapeutics Officer Jason V. Coloma Files Form 144 for Proposed Sale of 34,501 Shares

October 3, 2026 | kalkinemedia.comK

Maze Therapeutics (NASDAQ:MAZE) CMO Harold Bernstein Sells 16,141 Shares of Stock

October 3, 2026 | insidertrades.com

Maze Therapeutics (NASDAQ:MAZE) CEO Jason Coloma Sells 34,501 Shares of Stock

October 3, 2026 | americanbankingnews.com

Maze Therapeutics (NASDAQ:MAZE) Stock: Insider Atul Dandekar Sells 7,500 Shares

October 3, 2026 | americanbankingnews.com

Maze Therapeutics (NASDAQ:MAZE) Stock: Insider Harold Bernstein Sells 16,141 Shares

October 2, 2026 | marketbeat.com

Maze Therapeutics (NASDAQ:MAZE) Stock: Insider Jason Coloma Sells 34,501 Shares

October 2, 2026 | marketbeat.com

Maze Therapeutics (NASDAQ:MAZE) Insider Atul Dandekar Sells 7,500 Shares of Company Stock

October 2, 2026 | insidertrades.com

Maze Therapeutics (NASDAQ:MAZE) Insider Sells $202,950.00 in Stock

October 1, 2026 | marketbeat.com

Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives Average Rating of "Buy" from Analysts

October 1, 2026 | americanbankingnews.com

Maze Therapeutics, Inc. (NASDAQ:MAZE) Stock Has Consensus Price Target of $63.40

October 1, 2026 | marketbeat.com

Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 4.5% - Here's Why

September 28, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ARCT, MAZE, COAG, and ANAB Company Descriptions

AnaptysBio NASDAQ:ANAB

$46.59 -1.30 (-2.71%)

As of 12:46 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Arcturus Therapeutics NASDAQ:ARCT

$12.77 -0.23 (-1.75%)

As of 12:47 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Hemab Therapeutics NASDAQ:COAG

$28.45 +0.08 (+0.28%)

As of 12:22 PM Eastern

We are a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Coagulation disorders encompass a broad and heterogeneous group of conditions, and many patients experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches. Our lead asset, sutacimig (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Our second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. We are also advancing multiple preclinical and discovery-stage assets. We estimate that there are approximately an aggregate of 10,000 patients with Glanzmann thrombasthenia and Factor VII deficiency and an aggregate of 120,000 patients with Von Willebrand Disease in the geographies where we intend to commercialize our assets, including the United States, the European Union, Japan, the Gulf Cooperation Council countries and other select regions. With greater disease burden awareness, potential regulatory approvals of new prophylactic options and expanding global reach of these options, we believe the overall number of addressable patients for our clinical-stage assets, and preclinical and discovery stage programs could be greater than we currently estimate. We aim to establish the industry’s leading coagulation franchise through the execution of our “Hemab 2x3 by 2030” strategic roadmap, which is designed to build a franchise consisting of 2 commercial medicines, 2 new late-stage clinical programs, and 2 new early-stage clinical programs by 2030. We have not yet initiated pivotal trials for any of our product candidates, and due to the novel and unproven nature of our programs, their current stage of development and the lack of approved prophylactic therapies to inform endpoint selection and trial design, we may not be able to achieve our strategic goals on the timeline we expect or at all. Our principal executive offices are located in Cambridge, MA.

Maze Therapeutics NASDAQ:MAZE

$26.20 -0.23 (-0.88%)

As of 12:47 PM Eastern

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. Our goal is to bring novel precision medicines to patients to maximize our impact on human health. CKD is a serious, progressive condition that affects approximately 37 million patients in the United States, where it is expected to be the fifth most prevalent chronic disease by 2040. Current treatments for CKD consider patients as falling into clinical categories and focus on slowing the progression of disease, but do not target the underlying genetic drivers of disease. Our lead programs are designed to phenocopy, or mimic, the protective effects of certain genetic variants that are associated with reduced disease burden and improved kidney function in distinct groups of CKD patients. Our most advanced lead program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD, which is estimated to affect over one million patients in the United States alone. Although the link between APOL1 variants and renal dysfunction has been known for over a decade, we have identified a new protective variant that underpins our therapeutic approach for MZE829 and may ultimately allow us to address a broader population of AKD than has previously been possible in the clinical setting. In October 2024, we reported results for our Phase 1 clinical trial of MZE829, in which we enrolled 111 healthy patients who received either single or multiple ascending doses of 20 mg to 480 mg of MZE829 administered daily. Treatment was well tolerated with no severe adverse events or serious adverse events reported in patients treated with single doses up to 480 mg and multiple doses of up to 350 mg daily for seven days. Dose-proportional pharmacokinetics, or PK, was observed with low variability (10-40%) across doses. We initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose our first patient in the first quarter of 2025 and to report proof of concept data in the first quarter of 2026. Our second lead program, MZE782, is an oral, small molecule inhibitor of the solute transporter SLC6A19, a novel CKD target, with the potential to address approximately five million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens or as an alternative option for those patients who do not adequately respond to today’s standard of care. We initiated a Phase 1 trial of MZE782 in September 2024 and expect to report initial data from this trial in the second half of 2025. In addition to CKD, we believe MZE782 may provide benefit to patients suffering from the genetically defined metabolic disease, phenylketonuria, or PKU. Following our ongoing Phase 1 trial of MZE782, we plan to conduct a parallel Phase 2 clinical trial to explore MZE782 as a potential treatment of PKU. Our Compass platform supports end-to-end variant identification and functionalization capabilities as well as advanced research tools and methodologies for drug development. We believe the process of variant functionalization, or understanding how genetic variants function to affect the course of disease, is a foundational aspect of precision medicine and one of the core capabilities that sets us apart from others in the field. We were incorporated under the laws of the State of Delaware on August 29, 2017, originally under the name Genetic Modifiers NewCo, Inc. We changed our name on July 5, 2018 to Modulus Therapeutics, Inc. and on September 25, 2018, to Maze Therapeutics, Inc. Our principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARCT, MAZE, COAG, and ANAB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARCT, MAZE, COAG, and ANAB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARCT, MAZE, COAG, and ANAB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ARCT, MAZE, COAG, and ANAB Company Descriptions

AnaptysBio NASDAQ:ANAB

Arcturus Therapeutics NASDAQ:ARCT

Hemab Therapeutics NASDAQ:COAG

Maze Therapeutics NASDAQ:MAZE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARCT, MAZE, COAG, and ANAB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARCT, MAZE, COAG, and ANAB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARCT, MAZE, COAG, and ANAB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ARCT, MAZE, COAG, and ANAB Company Descriptions

AnaptysBio NASDAQ:ANAB

Arcturus Therapeutics NASDAQ:ARCT

Hemab Therapeutics NASDAQ:COAG

Maze Therapeutics NASDAQ:MAZE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools